Intravenous Recombinant Tissue Plasminogen Activator in Acute Thrombotic Stroke: Study Design, Recanalization, and Clinical Outcome
The study of the efficacy of thrombolytic agents in the treatment of acute stroke derives from the observation that stroke is typically an atherothrombotic or thromboembolic process [1, 6], Careful intraarterial infusion of the thrombolytic agents urokinase (u-PA) and streptokinase may lead to thrombus dissolution and clinical improvement in selected patients presenting with acute thrombotic or thromboembolic stroke [1, 2–4 7], This experience has provided the practical background for the evaluation of the relatively fibrin specific agent recombinant tissue plasminogen activator (rt-PA) delivered by intravenous infusion. A predominantly two-chain rt-PA preparation (duteplase, Burroughs Wellcome, Beckenham, UK) has been employed in a prospective open multicenter dose-rate safety and efficacy study of thrombolysis m acute thrombotic and thromboembolic stroke.
KeywordsAcute Stroke Hemorrhagic Transformation Recombinant Tissue Plasminogen Activator Hemorrhagic Infarction Thromboembolic Stroke
Unable to display preview. Download preview PDF.
- 5.rt-PA Acute Stroke Study Group (1990) An open multicenter study of the safety and efficacy of various doses of t-PA in patients with acute stroke: A progress report. Stroke 21:181Google Scholar